@article{99a2947c3c5e4a1599f8fdbb869643c3,
title = "Ipilimumab and Nivolumab in Rare Tumors S1609: Neuroendocrine—Response",
author = "{On Behalf of the S1609 Team} and Patel, {Sandip P.} and Megan Othus and Chae, {Young Kwang} and Razelle Kurzrock",
note = "Funding Information: M. Othus is an employee/paid consultant for Merck, and reports receiving other remuneration from Celgene and Glycomimetics. Y.K. Chae reports receiving commercial research grants from Abbvie, Bristol-Myers Squibb, Freenome, Lexent Bio, and Biodesix, and speakers bureau honoraria from Bristol-Myers Squibb, Lilly Oncology, AstraZeneca, Genentech, Pfizer, Foundation Medicine, Biodesix, and Guardant Health. R. Kurzrock is an employee/paid consultant for Gaido, LOXO, X-Biotech, Actuate Therapeutics, Roche, NeoMed, Soluventis, Pfizer, and Merck, reports receiving commercial research grants from Incyte, Genentech, Merck Serono, Pfizer, Sequenom, Foundation Medicine, Guardant Health, Grifols, Konica Minolta, DeBiopharm, Boerhringer Ingelheim, and OmniSeq, speakers bureau honoraria from Roche, and other remuneration from IDbyDNA, CureMatch, Inc., CureMetrix, Inc., and Soluventis. No potential conflicts of interest were disclosed by the other authors.",
year = "2020",
month = may,
day = "15",
doi = "10.1158/1078-0432.CCR-20-0790",
language = "English (US)",
volume = "26",
pages = "2434",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "10",
}
